AMERICAS

Latin America continues to dominate this region, with Mexico and Brazil being the most significant contributors to the region’s performance. There is one manufacturing site in this region which is situated in Brazil and which focuses on finished dose form (“FDF”). The region commercialises internationally recognised medicines across the prescription, hospital and over-the-counter (“OTC”) channels.

Key Countries

Brazil
Canada
Chile
Colombia
Ecuador
Mexico
USA

KEY BRANDS

Brand		Therapeutic category
Diprivan		General anaesthetic
Meticorten		Corticosteroid
Milk of Magnesia		Antacids-antiflatulants
Perfalgen		Analgesic injectable
Xylocaine		Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

714

June 2022

768

June 2021

STATISTICS

Number of products launched:

20

(2021: 3)

Number of product recalls:

1

(2021: 1)

Average staff turnover:

22%

(2021: 14%)

Number of work-related fatalities:

Nil

(2021: Nil)

Sales representatives:

235

(2021: 235)

Revenue	2022 R’million	2021 (CER) R’million	Change %

Commercial Pharmaceuticals
Regional Brands	2 856	2 636	8
Sterile Focus Brands	1 439	1 400	3

Total	4 295	4 036	6

Note: Commercial Pharmaceuticals revenue is by customer geography.

The Mexican pharmaceutical market grew 8% to EUR9,01 billion MAT June 2022, positively impacted by growth across the generic, ethical and OTC markets.
Pharmaceutical sales across the total Spanish Latin America market grew 13,6% to EUR22,5 billion MAT June 2022.

Source: IQVIA – June 2022
MAT= Moving annual total